PD-L2 could independently exert predictive power in the progression-free survival, and a longer survival was observed in the cancer patients with PD-L2-positive status than those with PD-L2-negative after receiving pembrolizumab therapy [58]. This evidence concerns the gene PDCD1LG2 and cancer.